Mechanism of Action of the LAT1 Inhibitor Being Developed by Our Company
NEWS
-
- 2026.08.04
-
J-Pharma President and CEO Masuhiro Yoshitake Featured in BioSpectrum Asia Interview
-
- 2026.07.23
-
J-Pharma Announces First Patient Dosed in Investigator-Initiated Trial Evaluating LAT1 Inhibitor Nanvuranlat in Combination with ICIs in First-Line Biliary Tract Cancer
-
- 2026.06.16
-
J Pharma Co., Ltd. and Uniphar Announce Advancement of Nanvuranlat into Phase 3 Clinical Development Following FDA Alignment and Initial Patient Enrollment Strategic partnership enables direct progression to Phase 3, bypassing additional Phase 2 study, as first patients are randomized in global trial
